Evidence map›Paper›PMID 38396398›Full record

ReviewDiagnostics (Basel, Switzerland)2024

A Comprehensive Review of COVID-19-Related Olfactory Deficiency: Unraveling Associations with Neurocognitive Disorders and Magnetic Resonance Imaging Findings.

Ludovica Simonini, Francesca Frijia, Lamia Ait Ali, Ilenia Foffa, Cecilia Vecoli, Carmelo De Gori, Sara De Cori, Monica Baroni, Giovanni Donato Aquaro, Carlo Maremmani and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Olfactory Dysfunction and Cognitive Decline: Are They Related?Current allergy and asthma reports · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ludovica SimoniniInstitute of Clinical Physiology, National Research Council (CNR), 54100 Massa, Italy.
Francesca FrijiaBioengineering Unit, Fondazione Toscana G. Monasterio, 56124 Pisa, Italy.
Lamia Ait AliInstitute of Clinical Physiology, National Research Council (CNR), 54100 Massa, Italy.
Ilenia FoffaInstitute of Clinical Physiology, National Research Council (CNR), 54100 Massa, Italy.ORCID 0000-0002-4604-0871
Cecilia VecoliInstitute of Clinical Physiology, National Research Council (CNR), 54100 Massa, Italy.ORCID 0000-0002-5921-3604
Carmelo De GoriDepartment of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy.
Sara De CoriDepartment of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy.
Monica BaroniFondazione "G. Monasterio" CNR-Regione Toscana, 54100 Massa, Italy.
Giovanni Donato AquaroAcademic Radiology Unit, Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56124 Pisa, Italy.ORCID 0000-0003-0915-915X
Carlo MaremmaniUnit of Neurology, Ospedale Apuane, Azienda USL Toscana Nord Ovest, 54100 Massa, Italy.
Francesco LombardoDepartment of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy.
Fondazione Toscana Gabriele Monasterio · ITIstituto di Fisiologia Clinica · ITAzienda Usl Toscana Centro · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olfactory dysfunction (OD) is one of the most common symptoms in COVID-19 patients and can impact patients' lives significantly. The aim of this review was to investigate the multifaceted impact of COVID-19 on the olfactory system and to provide an overview of magnetic resonance (MRI) findings and neurocognitive disorders in patients with COVID-19-related OD. Extensive searches were conducted across PubMed, Scopus, and Google Scholar until 5 December 2023. The included articles were 12 observational studies and 1 case report that assess structural changes in olfactory structures, highlighted through MRI, and 10 studies correlating the loss of smell with neurocognitive disorders or mood disorders in COVID-19 patients. MRI findings consistently indicate volumetric abnormalities, altered signal intensity of olfactory bulbs (OBs), and anomalies in the olfactory cortex among COVID-19 patients with persistent OD. The correlation between OD and neurocognitive deficits reveals associations with cognitive impairment, memory deficits, and persistent depressive symptoms. Treatment approaches, including olfactory training and pharmacological interventions, are discussed, emphasizing the need for sustained therapeutic interventions. This review points out several limitations in the current literature while exploring the intricate effects of COVID-19 on OD and its connection to cognitive deficits and mood disorders. The lack of objective olfactory measurements in some studies and potential validity issues in self-reports emphasize the need for cautious interpretation. Our research highlights the critical need for extensive studies with larger samples, proper controls, and objective measurements to deepen our understanding of COVID-19's long-term effects on neurological and olfactory dysfunctions.

Indexed as

anosmiaCOVID-19imagingmood disordersMRIneurocognitiveolfactoryolfactory training

Identifiers

PMID38396398
PMCPMC10888385
OpenAlexW4391613397

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.